The Aquila Study Strongly Supports the Benefit of Early Intervention with Daratumumab Monotherapy in Patients with High-Risk Smoldering Multiple Myeloma
Daratumumab monotherapy demonstrates a clinically meaningful and significant benefit in preventing or delaying progression to active multiple myeloma in patients with high-risk smoldering multiple myeloma. According to Fredrik Schjesvold, Oslo Myeloma Center, the Aquila study was the most interesting trial for multiple myeloma during ASH 2024.
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen